{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:51:47Z","timestamp":1781949107119,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00535-026-02383-8","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:33:34Z","timestamp":1773110014000},"page":"953-961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5152-5697","authenticated-orcid":false,"given":"Nanae","family":"Tsuruoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Takedomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Sakemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ashizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nishimata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Kanmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoki","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2383_CR1","doi-asserted-by":"publisher","DOI":"10.2471\/B09127","volume-title":"WHO consolidated guidelines on tuberculosis: module 1: prevention\u2014tuberculosis preventive treatment","author":"World Health Organisation","year":"2024","unstructured":"World Health Organisation. WHO consolidated guidelines on tuberculosis: Module 1: prevention\u2014tuberculosis preventive treatment, 2 edn. Geneva: World Health Organization; 2024.","edition":"2"},{"key":"2383_CR2","unstructured":"Tuberculosis Surveillance Center. Tuberculosis in Japan: annual report 2024. Tokyo: Department of Epidemiology and Clinical Research, the Research Institute of Tuberculosis; 2024. https:\/\/jata-ekigaku.jp\/english\/tb-in-japan, accessed 29 Sep 2025."},{"key":"2383_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/jpm12030507","volume":"12","author":"CH Park","year":"2022","unstructured":"Park CH, Park JH, Jung YS. Impact of immunosuppressive therapy on the performance of latent tuberculosis screening tests in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Pers Med. 2022;12:507.","journal-title":"J Pers Med"},{"key":"2383_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403:1177\u201391.","journal-title":"Lancet"},{"key":"2383_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571\u201384.","journal-title":"Lancet"},{"key":"2383_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642:458\u201366.","journal-title":"Nature"},{"key":"2383_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-025-02295-z","author":"A Tsutsui","year":"2025","unstructured":"Tsutsui A, Murakami Y, Nishiwaki Y, et al. Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn\u2019s disease in Japan in 2023. J Gastroenterol. 2025. https:\/\/doi.org\/10.1007\/s00535-025-02295-z. (Online ahead of print).","journal-title":"J Gastroenterol"},{"key":"2383_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","volume":"15","author":"T Kucharzik","year":"2021","unstructured":"Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15:879\u2013913.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 3","key":"2383_CR9","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut"},{"key":"2383_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5217\/ir.2018.16.1.4","volume":"16","author":"DI Park","year":"2018","unstructured":"Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. Intest Res. 2018;16:4\u201316.","journal-title":"Intest Res"},{"key":"2383_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol"},{"key":"2383_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/apt.16952","volume":"56","author":"SR Fehily","year":"2022","unstructured":"Fehily SR, Al-Ani AH, Abdelmalak J, et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression\u2014risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022;56:6\u201327.","journal-title":"Aliment Pharmacol Ther"},{"key":"2383_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/ibd\/izx019","volume":"24","author":"RK Vajravelu","year":"2017","unstructured":"Vajravelu RK, Osterman MT, Aberra FN, et al. Indeterminate quantiferon-TB gold increases likelihood of inflammatory bowel disease treatment delay and hospitalization. Inflamm Bowel Dis. 2017;24:217\u201326.","journal-title":"Inflamm Bowel Dis"},{"key":"2383_CR14","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s10620-018-5178-1","volume":"63","author":"T Al-Taweel","year":"2018","unstructured":"Al-Taweel T, Strohl M, Pai M, et al. A study of optimal screening for latent tuberculosis in patients with inflammatory bowel disease. Dig Dis Sci. 2018;63:2695\u2013702.","journal-title":"Dig Dis Sci"},{"key":"2383_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/flgastro-2017-100951","volume":"9","author":"AA Thi","year":"2018","unstructured":"Thi AA, Abbara A, Bouri S, et al. Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study. Frontline Gastroenterol. 2018;9:234\u201340.","journal-title":"Frontline Gastroenterol"},{"key":"2383_CR16","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1097\/MIB.0000000000000147","volume":"20","author":"SH Wong","year":"2014","unstructured":"Wong SH, Ip M, Tang W, et al. Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014;20:2067\u201372.","journal-title":"Inflamm Bowel Dis"},{"key":"2383_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/1751-2980.12437","volume":"18","author":"DJ Song","year":"2017","unstructured":"Song DJ, Tong JL, Peng JC, et al. Tuberculosis screening using igra and chest computed tomography in patients with inflammatory bowel disease: a retrospective study. J Dig Dis. 2017;18:23\u201330.","journal-title":"J Dig Dis"},{"key":"2383_CR18","volume":"2021","author":"AK Mantri","year":"2021","unstructured":"Mantri AK, Meena P, Puri AS, et al. Comparison of interferon-gamma release assay and tuberculin skin test for the screening of latent tuberculosis in inflammatory bowel disease patients: Indian scenario. Tuberc Res Treat. 2021;2021:6682840.","journal-title":"Tuberc Res Treat"},{"key":"2383_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","volume":"115","author":"S Kedia","year":"2020","unstructured":"Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115:340\u20139.","journal-title":"Am J Gastroenterol"},{"key":"2383_CR20","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3201\/eid2411.171948","volume":"24","author":"T Nishimura","year":"2018","unstructured":"Nishimura T, Ota M, Mori M, et al. Estimating latent tuberculosis infection using interferon-\u03b3 release assay. Japan Emerg Infect Dis. 2018;24:2111\u20133.","journal-title":"Japan Emerg Infect Dis"},{"key":"2383_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5217\/ir.2024.00076","volume":"23","author":"K Fujimoto","year":"2025","unstructured":"Fujimoto K, Hosomi S, Kobayashi Y, et al. Tuberculosis risk in patients with Crohn\u2019s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database. Intest Res. 2025;23:309\u201317.","journal-title":"Intest Res"},{"key":"2383_CR22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/apt.16839","volume":"55","author":"P Kumar","year":"2022","unstructured":"Kumar P, Vuyyuru SK, Kante B, et al. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther. 2022;55:1431\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"2383_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.21705","volume":"55","author":"SS Jick","year":"2006","unstructured":"Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19\u201326.","journal-title":"Arthritis Rheum"},{"key":"2383_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7110394","volume":"7","author":"MT Weng","year":"2018","unstructured":"Weng MT, Tung CC, Chang YT, et al. Trends of medication usage and associated outcomes for Taiwanese patients with inflammatory bowel disease from 2001 to 2015. J Clin Med. 2018;7:394.","journal-title":"J Clin Med"},{"key":"2383_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148\u201355.","journal-title":"Lancet Infect Dis"},{"key":"2383_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3109\/07853890.2014.941919","volume":"46","author":"R Lorenzetti","year":"2014","unstructured":"Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med. 2014;46:547\u201354.","journal-title":"Ann Med"},{"key":"2383_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"2383_CR28","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253\u201362.","journal-title":"Ann Rheum Dis"},{"key":"2383_CR29","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"2383_CR30","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.4049\/jimmunol.167.12.6957","volume":"167","author":"C H\u00f6lscher","year":"2001","unstructured":"H\u00f6lscher C, Atkinson RA, Arendse B, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol. 2001;167:6957\u201366.","journal-title":"J Immunol"},{"key":"2383_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/ibd\/izad032","volume":"30","author":"R Liu","year":"2024","unstructured":"Liu R, Li Z, Ye L, et al. Risk of tuberculosis and Hepatitis B reactivation in patients with Crohn\u2019s disease on ustekinumab: a nationwide real-world study. Inflamm Bowel Dis. 2024;30:45\u201352.","journal-title":"Inflamm Bowel Dis"},{"key":"2383_CR32","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437\u201344.","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02383-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:44:47Z","timestamp":1781948687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02383-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02383-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.A. reports lecture fees from Kissei Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Pfizer Japan Inc., AbbVie G.K., EA Pharma Co., Ltd, Gilead Sciences Inc., Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd, Janssen Pharmaceutical K.K., and research grants from Pfizer Japan Inc., outside of the submitted work. S.Y. reports lecture fees from AbbVie G.K., EA Pharma Co., Ltd, Gilead Sciences Inc., Mochida Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., S.Y. reports lecture fees from Mochida Pharmaceutical Co., Ltd. F.H. reports research grants from AbbVie G.K., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., MSD K.K. Co., Ltd. scholarship donation from AbbVie G.K., Mochida Pharmaceutical Co., KYORIN Pharmaceutical Co., Ltd., and lecture fees from AbbVie G.K., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Takeda Co., Ltd., outside of the submitted work. M.E. reports lecture fees from AbbVie G.K., Takeda Pharmaceutical Co., EA Pharma Co., Ltd, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Pfizer Japan Inc., Gilead Sciences, Inc., Tanabe Pharma Corporation, and Bristol Myers Squibb outside of the submitted work. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}